Park Avenue Securities LLC Reduces Stock Position in United Therapeutics Corporation $UTHR

Park Avenue Securities LLC decreased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 58.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 984 shares of the biotechnology company’s stock after selling 1,369 shares during the quarter. Park Avenue Securities LLC’s holdings in United Therapeutics were worth $412,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $29,000. WealthCollab LLC grew its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. raised its holdings in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Geneos Wealth Management Inc. raised its holdings in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the last quarter. Finally, True Wealth Design LLC lifted its stake in shares of United Therapeutics by 738.5% during the 3rd quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 96 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on UTHR shares. Morgan Stanley set a $447.00 target price on United Therapeutics in a research note on Wednesday, October 29th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. HC Wainwright increased their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. UBS Group raised their target price on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, Wells Fargo & Company upped their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $509.50.

Insider Buying and Selling at United Therapeutics

In other news, Director Christopher Causey sold 1,000 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total value of $510,000.00. Following the completion of the sale, the director owned 4,190 shares of the company’s stock, valued at $2,136,900. This represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jan Malcolm sold 50 shares of the stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $512.12, for a total value of $25,606.00. Following the completion of the sale, the director owned 420 shares of the company’s stock, valued at approximately $215,090.40. This trade represents a 10.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 597,814 shares of company stock valued at $280,924,148 in the last quarter. Company insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

UTHR opened at $464.93 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99. The firm has a 50 day moving average price of $486.85 and a 200 day moving average price of $408.02. The company has a market cap of $20.02 billion, a PE ratio of 17.62, a price-to-earnings-growth ratio of 2.45 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the previous year, the company posted $6.39 earnings per share. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. On average, sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.